Contract research organization and genome-scale diagnostics services company
Sign up today and learn more about Personalis Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Personalis Stock
Personalis combines expertise both in the technology of sequencing and in interpretation, with an extensive history of peer reviewed publication and commercial success. Broad adoption of medical genome interpretation will require accuracy befitting regulatory approval, both in variant detection and interpretation. More than half of the founding team are MDs, and this reflects the company's commitment to serious medically-focused results, at quality standards eventually suitable for regulatory approval and insurance reimbursement. The team includes experienced PhD scientists, who know that the research community also cares deeply about accuracy, thoroughly substantiated and peer-reviewed. Personalis has exclusively licensed key intellectual property originating in the labs of the founders. Lastly, the Personalis team includes business people with decades of experience in genetic analysis, who know that the democratization of genome sequencing will also require high-quality customer support for interpretation, lab by lab, genome after genome.
Chief Executive Officer
Vice President Finance and Administration
Carol J. Tillis
Senior Director of Genomic Services
Chief Science Officer
Co-founder and Scientific Advisor